Azenta, Inc. is a global leader specializing in advanced solutions for the discovery, handling, and preservation of life science samples. The company's ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $0.38 · Revenue $614.97M · 2 analysts
Est. EPS $0.12 · Revenue $154.99M · 2 analysts
Est. EPS $0.13 · Revenue $155.32M · 1 analysts
Est. EPS $0.17 · Revenue $161.45M · 1 analysts
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $593.8M | +3.6% | +11.3% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-55.8M | +66.2% | +101.5% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +45.5% | +2.5% | +4.8% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -1.9% | +63.7% | +75.4% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -9.4% | +67.3% | +101.4% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $38.3M | +210.3% | -180.8% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | +6.5% | +199.6% | -172.6% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 6.4% | +61.1% | -0.3% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 2.98x | -26.7% | -11.6% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $2.1B | -1.9% | -1.5% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -1.22 vs 0.50 | -342.7% | 0.05 vs 0.11 | -56.1% |
| Revenue Surprise | $593.8M vs $591.0M | +0.5% | $161.2M vs $149.3M | +8.0% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Aug 9, 2026 | Pirogova Olga | officer: SVP and CHRO | Common | D | 1,085 | $32.04 |
| Jul 31, 2026 | Starr Ephraim | officer: SVP, Gen Counsel & Secretary | Common | A | 335 | $24.17 |
| May 18, 2026 | Cornog William L | director | Common | A | 10,000 | $16.38 |
| May 15, 2026 | Starr Ephraim | officer: SVP, Gen Counsel & Secretary | Common | D | 3,621 | $16.02 |
| Apr 28, 2026 | MARTIN WILLIAM E. III | officer: President Multiomics | Common | A | 17,790 | $24.24 |
Operator: Greetings, and welcome to Azenta Q3 2026 Fiscal Financial Results. [Operator Instructions] As a reminder, this conference is being recorded, Wednesday, August 5, 2026. I will now turn the conference over to Yvonne Perron, Vice President, FP&A and Investor Relations. Yvonne Perron: Thank you, operator, and good morning, and welcome to everyone joining us today. We would like to welcome you to our earnings conference call for the third quarter of fiscal year 2026. Our third quarter earnings press release was issued yesterday after market and is available on our Investor Relations website located at investors.azenta.com in addition to the PowerPoint slides and the supplementary information that will be used during the prepared remarks today. Please note that effective the first fiscal quarter of 2025, the results of B Medical Systems are treated as discontinued operations. The previously disclosed sale of the B Medical Systems business was completed on July 1, 2026. I would like to remind everyone that during the course of the call, we will be making a number of forward-looking statements within the meaning of the Private Litigation Securities Act of 1995. There are many factors that may cause actual financial results or other events to differ from those identified in such forward-looking statements. I would refer you to the section of our earnings release titled Safe Harbor Statement, the safe harbor slide on the aforementioned PowerPoint presentation on our website and our various filings with the SEC, including our annual reports on Form 10-K and our quarterly reports on Form 10-Q. We make no obligation to update these statements should future financial data or events occur that differ from the forward-looking statements presented today. We may refer to a number of non-GAAP financial measures, which are used in addition to and in conjunction with results presented in accordance with GAAP. We believe the non-GAAP measures provide an additional way of viewing aspects of our operations and performance, but when considered with GAAP financial results and the reconciliation of GAAP measures, they provide an even more complete understanding of the Azenta business. Non-GAAP measures should not be relied upon to the exclusion of the GAAP measures themselves. On the call with me today is our President and Chief Executive Officer, John Marotta; and our Executive Vice President and Chief Financial Officer, Lawrence Lin. We will begin the call with opening remarks from John, followed by Lawrence, who will provide a detailed review of our financial results and our outlook for fiscal year 2026. We will then take your questions at the end of the prepared remarks. With that, I would like to turn the call over to our CEO, John Marotta. John P. Marotta: Good morning, everyone, and thank you for joining us today. In the third quarter, despite an uneven and challenging market, we made substantial progress delivering against our commitments towards …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
John Marotta | President, Chief Executive Officer & Director | USD 1,985,118 | Male | 1981 | Active |
Lawrence Y. Lin | Executive Vice President & Chief Financial Officer | USD 1,125,036 | Male | 1977 | Active |
Ginger Zhou | Advisor | USD 680,780 | — | 1977 | Active |
Olga Pirogova | Senior Vice President & Chief HR Officer | USD 660,694 | Female | 1974 | Active |
Ephraim Starr | Senior Vice President, General Counsel & Corporate Secretary | USD 653,909 | Male | 1972 | Active |
Alex Esmon | Vice President and General Manager of Sample Repository Solutions | — | Male | — | Active |
William E. Martin | Senior Vice President & President of Multiomics | — | Male | 1975 | Active |
Michael Paulo | Vice President, Chief Information & Digital Officer | — | Male | — | Active |
Andrea O'Hara | Strategic Technical Specialist of Azenta Life Sciences | — | — | — | Active |
Yvonne Perron | Vice President of Financial Planning & Analysis and Investor Relations | — | Female | — | Active |
BURLINGTON, Mass., Aug. 4, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the third quarter ended June 30, 2026.
American Capital Management Inc. lifted its holdings in Azenta, Inc. (NASDAQ: AZTA) by 26.9% during the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,296,024 shares of the company's stock after buying an additional 274,588 shares during the quarter. Azenta makes up
BURLINGTON, Mass., July 22, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal third quarter 2026 earnings which ended on June 30, 2026, on Tuesday, August 4, 2026, after the market closes.
BURLINGTON, Mass., July 8, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced the completion of the previously disclosed sale of its B Medical Systems business to Thelema S.
NEW YORK, June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Azenta, Inc. ("Azenta" or the "Company") (NASDAQ: AZTA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
